Statistics at a Glance
At a Glance
Estimated New Cases in 2023 81,800
% of All New Cancer Cases 4.2%
Estimated Deaths in 2023 14,890
% of All Cancer Deaths 2.4%
|Year||Rate of New Cases — SEER 8||Rate of New Cases — SEER 12||Death Rate — U.S.||5-Year Relative Survival — SEER 8|
|Observed||Modeled Trend||Observed||Modeled Trend||Observed||Modeled Trend||Observed||Modeled Trend|
New cases come from SEER 12. Deaths come from U.S. Mortality.
All Races, Both Sexes. Rates are Age-Adjusted.
Modeled trend lines were calculated from the underlying rates using the Joinpoint Trend Analysis Software.
The 2020 incidence rate is displayed but not used in the fit of the trend line(s). Impact of COVID on SEER Cancer Incidence 2020 data
New cases are also referred to as incident cases in other publications. Rates of new cases are also referred to as incidence rates.
Rate of New Cases and Deaths per 100,000: The rate of new cases of kidney and renal pelvis cancer was 17.2 per 100,000 men and women per year. The death rate was 3.5 per 100,000 men and women per year. These rates are age-adjusted and based on 2016–2020 cases and deaths.
Lifetime Risk of Developing Cancer: Approximately 1.8 percent of men and women will be diagnosed with kidney and renal pelvis cancer at some point during their lifetime, based on 2017–2019 data.
Prevalence of This Cancer: In 2020, there were an estimated 628,355 people living with kidney and renal pelvis cancer in the United States.
How Many People Survive 5 Years Or More after Being Diagnosed with Kidney and Renal Pelvis Cancer?
Relative survival is an estimate of the percentage of patients who would be expected to survive the effects of their cancer. It excludes the risk of dying from other causes. Because survival statistics are based on large groups of people, they cannot be used to predict exactly what will happen to an individual patient. No two patients are entirely alike, and treatment and responses to treatment can vary greatly.
Based on data from SEER 22 (Excluding IL/MA) 2013–2019. Gray figures represent those who have died from kidney and renal pelvis cancer. Green figures represent those who have survived 5 years or more.
Survival by Stage
Cancer stage at diagnosis, which refers to extent of a cancer in the body, determines treatment options and has a strong influence on the length of survival. In general, if the cancer is found only in the part of the body where it started it is localized (sometimes referred to as stage 1). If it has spread to a different part of the body, the stage is regional or distant. The earlier kidney and renal pelvis cancer is caught, the better chance a person has of surviving five years after being diagnosed. For kidney and renal pelvis cancer, 65.8% are diagnosed at the local stage. The 5-year relative survival for localized kidney and renal pelvis cancer is 92.9%.
|Stage||Percent of Cases||5-Year Relative Survival|
Confined to Primary Site
Spread to Regional Lymph Nodes
Cancer Has Metastasized
SEER 22 (Excluding IL/MA) 2013–2019, All Races, Both Sexes by SEER Combined Summary Stage
New Cases and Deaths
How Common Is This Cancer?
Compared to other cancers, kidney and renal pelvis cancer is fairly common.
|Rank||Common Types of Cancer||Estimated New
|1.||Breast Cancer (Female)||297,790||43,170|
|3.||Lung and Bronchus Cancer||238,340||127,070|
|5.||Melanoma of the Skin||97,610||7,990|
|7.||Kidney and Renal Pelvis Cancer||81,800||14,890|
Kidney and renal pelvis cancer represents 4.2% of all new cancer cases in the U.S.
In 2023, it is estimated that there will be 81,800 new cases of kidney and renal pelvis cancer and an estimated 14,890 people will die of this disease.
Who Gets This Cancer?
Kidney cancer is more common in men than women and among African Americans and American Indian and Alaska Native populations. The rate of new cases of kidney and renal pelvis cancer was 17.2 per 100,000 men and women per year based on 2016–2020 cases, age-adjusted.
|Non-Hispanic American Indian/Alaska Native||37.7|
|Non-Hispanic Asian/Pacific Islander||12.1|
|Non-Hispanic American Indian/Alaska Native||18.3|
|Non-Hispanic Asian/Pacific Islander||5.7|
SEER 22 2016–2020, Age-Adjusted
|Age Range||Percent of New Cases|
Kidney and renal pelvis cancer is most frequently diagnosed among people aged 65–74.
SEER 22 2016–2020, All Races, Both Sexes
Who Dies From This Cancer?
Kidney and renal pelvis cancer is the twelfth leading cause of cancer death in the United States. The death rate was 3.5 per 100,000 men and women per year based on 2016–2020 deaths, age-adjusted.
|Non-Hispanic American Indian/Alaska Native||9.3|
|Non-Hispanic Asian/Pacific Islander||2.4|
|Non-Hispanic American Indian/Alaska Native||3.9|
|Non-Hispanic Asian/Pacific Islander||1.0|
U.S. 2016–2020, Age-Adjusted
|Age Range||Percent of Deaths|
The percent of kidney and renal pelvis cancer deaths is highest among people aged 65–74.
U.S. 2016–2020, All Races, Both Sexes
Trends in Rates
Changes Over Time
Keeping track of new cases, deaths, and survival over time (trends) can help scientists understand whether progress is being made and where additional research is needed to address challenges, such as improving screening or finding better treatments.
Using statistical models for analysis, age-adjusted rates for new kidney and renal pelvis cancer cases have been rising on average 0.7% each year over 2010–2019. Age-adjusted death rates have been falling on average 1.5% each year over 2011–2020. 5-year relative survival trends are shown below.
Interactive Statistics with SEER*Explorer
- Create custom graphs and tables
- Download data and images
- Share links to results
SEER*Explorer is an interactive website that provides easy access to a wide range of SEER cancer statistics. It provides detailed statistics for a cancer site by gender, race, calendar year, age, and for a selected number of cancer sites, by stage and histology.Explore Additional Kidney and Renal Pelvis Cancer Statistics
More About This Cancer
Cancer and the Kidney
Figure: The kidney (including the surrounding fibrous tissue and fat layer, the renal pelvis, and the ureter) and the adrenal gland, as well as a close-up view of the renal pelvis.
This cancer forms in tissues of the kidneys. Kidney cancer includes renal cell carcinoma (cancer that forms in the lining of very small tubes in the kidney that filter the blood and remove waste products) and renal pelvis carcinoma (cancer that forms in the center of the kidney where urine collects). It also includes Wilms tumor, which is a type of kidney cancer that usually develops in children under the age of 5.
Here are some resources for learning more about kidney cancer.
- More about risk factors for kidney cancer
- More about symptoms and diagnosis of kidney cancer
- More about treatment options for kidney cancer
- More about clinical trials
- More about cancer prevention
All statistics in this report are based on statistics from SEER and the Centers for Disease Control and Prevention's National Center for Health Statistics. Most can be found within SEER*Explorer.
All material in this report is in the public domain and may be reproduced or copied without permission; citation as to source, however, is appreciated.
SEER Cancer Stat Facts: Kidney and Renal Pelvis Cancer. National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/statfacts/html/kidrp.html
These stat facts focus on population statistics that are based on the U.S. population. Because these statistics are based on large groups of people, they cannot be used to predict exactly what will happen to an individual patient. To see tailored statistics, browse SEER*Explorer. To see statistics for a specific state, go to the State Cancer Profiles.
The statistics presented in these stat facts are based on the most recent data available, most of which can be found in SEER*Explorer. In some cases, different year spans may be used.
Estimates of new cases and deaths for 2023 are projections made by the American Cancer Society (ACS), based on earlier reported data.
Cancer is a complex topic. There is a wide range of information available. These stat facts do not address causes, symptoms, diagnosis, treatment, follow-up care, or decision making, although links are provided to information in many of these areas.